Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Focus Groups as Used by the Food and Drug Administration (All Food and Drug Administration Regulated Products), 6802-6803 [2011-2665]
Download as PDF
6802
Federal Register / Vol. 76, No. 26 / Tuesday, February 8, 2011 / Notices
average of two TEAs and two
submissions of safety and effectiveness
data each year. Therefore, we estimated
the total annual reporting burden to be
2,560 hours. This number included 960
hours for preparing TEAs (two TEAs per
year times 480 hours per TEA) and
1,600 hours (two submissions of safety
and effectiveness data times 800 hours
per submission).
We received a submission from a
manufacturer that filed two TEAs
stating that our estimates in the 60-day
notice were too low. The submission
noted that the time spent on ‘‘gathering,
compiling, evaluating and preparing’’
the TEA and safety and effectiveness
submissions was ‘‘significantly greater’’
than what FDA had estimated in the
2002 TEA final rule and the more recent
60-day notice. The submission estimates
that approximately 1,526 hours are
required to prepare a TEA and
approximately 2,348 hours to prepare a
safety and effectiveness submission.
Because the information provided in
the submission is based on actual
experience by a TEA applicant, we agree
with the submission and are adjusting
our estimates in this document
accordingly. We continue to estimate
that we will receive two TEAs and two
safety and effectiveness submissions
each year. We now estimate that it will
take approximately 1,525 hours to
prepare a TEA and 2,350 hours to
prepare a comprehensive safety and
effectiveness submission.
The submission included, as part of
the estimated burden of safety and
effectiveness data submission, an
estimated burden to submit
environmental data. We agree with the
submission and are including the
environmental data in our estimated
burden of safety and effectiveness data
submission. In February 2010, we
published a call-for-data to request data
on the environmental impact of
amending OTC drug monographs to
include any of 13 active ingredients that
were found eligible for potential
inclusion in an OTC monograph
through the TEA process (75 FR 7606,
February 22, 2010). In that document,
we explain that a proposed rule that
would add an ingredient to an OTC drug
monograph would be subject to the
National Environmental Policy Act of
1969 (NEPA) (see 21 CFR 25.1). In order
to comply with NEPA, an
environmental assessment of such an
Agency action is required, unless we
determine that a categorical exclusion is
warranted (21 CFR 25.20(f)). Therefore,
in this document, the estimated burden
of collection for safety and effectiveness
data submission includes the burden to
collect environmental data to support
the application of any categorical
exclusion or to conduct an
environmental assessment, if necessary.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of respondents
Annual frequency per response
330.14(c) and (d) 2 ...............................................................
330.14(f) and (i) 3 .................................................................
2
2
1
1
2
2
1,525
2,350
3,050
4,700
Total ..............................................................................
........................
........................
........................
........................
7,750
21 CFR section
1 There
Total annual
responses
Hours per response
Total hours
are no capital costs or operating and maintenance costs associated with this collection of information.
2 TEA.
3 Safety
and effectiveness submission, including environmental data in accordance with 21 CFR 25.1.
Dated: February 2, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–2692 Filed 2–7–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0594]
srobinson on DSKHWCL6B1PROD with NOTICES
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Focus Groups as
Used by the Food and Drug
Administration (All Food and Drug
Administration Regulated Products)
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
SUMMARY:
VerDate Mar<15>2010
18:16 Feb 07, 2011
Jkt 223001
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by March 10,
2011.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0497. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3794, e-mail:
Jonnalynn.capezzuto@fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
has submitted the following proposed
collection of information to OMB for
review and clearance.
Focus Groups as Used by the Food and
Drug Administration (All FDARegulated Products)—(OMB Control
Number 0910–0497)—Extension
FDA conducts focus group interviews
on a variety of topics involving FDAregulated products, including drugs,
biologics, devices, food, tobacco, and
veterinary medicine.
Focus groups provide an important
role in gathering information because
they allow for a more indepth
understanding of consumers’ attitudes,
beliefs, motivations, and feelings than
do quantitative studies. Focus groups
serve the narrowly defined need for
direct and informal opinion on a
specific topic and as a qualitative
research tool have three major purposes:
• To obtain consumer information
that is useful for developing variables
and measures for quantitative studies,
• To better understand consumers’
attitudes and emotions in response to
topics and concepts, and
E:\FR\FM\08FEN1.SGM
08FEN1
6803
Federal Register / Vol. 76, No. 26 / Tuesday, February 8, 2011 / Notices
• To further explore findings
obtained from quantitative studies.
FDA will use focus group findings to
test and refine their ideas but will
generally conduct further research
before making important decisions, such
as adopting new policies and allocating
or redirecting significant resources to
support these policies.
In the Federal Register of November
30, 2010 (75 FR 74061), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity
Number of respondents
Annual frequency per response
Total annual
responses
Hours per response
Total hours
Focus Group Interviews .......................................................
1,440
1
1,440
1.75
2,520
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
BILLING CODE 4160–01–P
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Peter Zelazowski, PhD,
Scientific Review Officer, Division Of
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, 6100 Executive
Blvd., Room 5b01, Bethesda, MD 20892, 301–
435–6902, PETER.ZELAZOWSKI@NIH.GOV.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: February 2, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Annually, FDA projects about 20
focus group studies using 160 focus
groups with an average of 9 persons per
group, and lasting an average of 1.75
hours each. FDA is requesting this
burden for unplanned focus groups so
as not to restrict the Agency’s ability to
gather information on public sentiment
of its proposals in its regulatory and
communications programs.
Dated: February 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–2665 Filed 2–7–11; 8:45 am]
[FR Doc. 2011–2725 Filed 2–7–11; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
srobinson on DSKHWCL6B1PROD with NOTICES
Eunice Kennedy Shriver National
Institute Of Child Health & Human
Development; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group; Obstetrics and Maternal-Fetal
Biology Subcommittee.
Date: March 3, 2011.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Mar<15>2010
18:16 Feb 07, 2011
Jkt 223001
Time: 8:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Mona R. Trempe, PhD,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN12, Bethesda, MD
20892, 301–594–3998,
trempemo@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: February 2, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–2724 Filed 2–7–11; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Modeling the Scientific Workforce.
Date: February 24, 2011.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\08FEN1.SGM
08FEN1
Agencies
[Federal Register Volume 76, Number 26 (Tuesday, February 8, 2011)]
[Notices]
[Pages 6802-6803]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-2665]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0594]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Focus Groups as Used
by the Food and Drug Administration (All Food and Drug Administration
Regulated Products)
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by March
10, 2011.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0497.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850, 301-796-3794, e-mail:
Jonnalynn.capezzuto@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Focus Groups as Used by the Food and Drug Administration (All FDA-
Regulated Products)--(OMB Control Number 0910-0497)--Extension
FDA conducts focus group interviews on a variety of topics
involving FDA-regulated products, including drugs, biologics, devices,
food, tobacco, and veterinary medicine.
Focus groups provide an important role in gathering information
because they allow for a more indepth understanding of consumers'
attitudes, beliefs, motivations, and feelings than do quantitative
studies. Focus groups serve the narrowly defined need for direct and
informal opinion on a specific topic and as a qualitative research tool
have three major purposes:
To obtain consumer information that is useful for
developing variables and measures for quantitative studies,
To better understand consumers' attitudes and emotions in
response to topics and concepts, and
[[Page 6803]]
To further explore findings obtained from quantitative
studies.
FDA will use focus group findings to test and refine their ideas
but will generally conduct further research before making important
decisions, such as adopting new policies and allocating or redirecting
significant resources to support these policies.
In the Federal Register of November 30, 2010 (75 FR 74061), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual
Activity Number of frequency per Total annual Hours per Total hours
respondents response responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Focus Group Interviews............................................. 1,440 1 1,440 1.75 2,520
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Annually, FDA projects about 20 focus group studies using 160 focus
groups with an average of 9 persons per group, and lasting an average
of 1.75 hours each. FDA is requesting this burden for unplanned focus
groups so as not to restrict the Agency's ability to gather information
on public sentiment of its proposals in its regulatory and
communications programs.
Dated: February 1, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-2665 Filed 2-7-11; 8:45 am]
BILLING CODE 4160-01-P